Background: Dandy-Walker (DW) malformation is a rare and severe congenital anomaly of the posterior fossa affecting the development of the cerebellum and the fourth ventricle. Objective: The aim of this study was to investigate the epidemiology of DW malformation, using data from the European population-based registries of congenital anomalies in the European Surveillance of Congenital Anomalies network. Methods: Anonymous individual data on cases of DW malformation diagnosed in 2002–2015 from 28 registries in 17 countries were included. Prevalence, prenatal detection rate, proportions and types of associated anomalies were estimated. Cases of DW variant were considered and analysed separately. Results: Out of 8,028,454 surveyed births we identified a total of 734 cases, including 562 DW malformation cases and 172 DW variant cases. The overall prevalence of DW malformation was 6.79 per 100,000 births (95% CI 5.79–7.96) with 39.2% livebirths, 4.3% foetal deaths from 20 weeks gestational age, and 56.5% terminations of pregnancy after prenatal diagnosis of foetal anomaly at any gestation (TOPFA). The livebirth prevalence was 2.74 per 100,000 births (95% CI 2.08–3.61). The prenatal detection rate was 87.6%. Two-hundred and seventy-three cases (48.6%) had an isolated cerebral anomaly and 24.2, 19.2 and 5.5% cases were associated with other structural non-cerebral anomalies, chromosomal anomalies and genetic syndromes respectively. The prevalence of DW variant was 2.08 per 100,000 (95% CI 1.39–3.13). Conclusions: This European population-based study provides the epidemiological profile of DW malformation. All birth outcomes were analysed and TOPFA represented more than half of the cases. About 50% of the cases of DW malformation were associated with other non-cerebral anomalies. Large populations and all birth outcomes are essential in epidemiological studies of rare and severe congenital anomalies.

Keywords:
Dandy-Walker malformation, Dandy-Walker variant, Epidemiology, Prevalence, EUROCAT
1.
Incesu L, Khosla A. Imaging in Dandy-Walker Malformation. Medscape Reference. March 27, 2018. Available from: http://emedicine.medscape.com/article/408059-overview.
2.
Bosemani T, Orman G, Boltshauser E, Tekes A, Huisman TA, Poretti A. Congenital abnormalities of the posterior fossa.
Radiographics
. 2015 Jan-Feb;35(1):200–20.
3.
Reeder MR, Botto LD, Keppler-Noreuil KM, Carey JC, Byrne JL, Feldkamp ML; National Birth Defects Prevention Study. Risk factors for Dandy-Walker malformation: a population-based assessment.
Am J Med Genet A
. 2015 Sep;167A(9):2009–16.
4.
Parisi MA, Dobyns WB. Human malformations of the midbrain and hindbrain: review and proposed classification scheme.
Mol Genet Metab
. 2003 Sep-Oct;80(1-2):36–53.
5.
Spennato P, Mirone G, Nastro A, Buonocore MC, Ruggiero C, Trischitta V, et al. Hydrocephalus in Dandy-Walker malformation.
Childs Nerv Syst
. 2011 Oct;27(10):1665–81.
6.
Stambolliu E, Ioakeim-Ioannidou M, Kontokostas K, Dakoutrou M, Kousoulis AA. The Most Common Comorbidities in Dandy-Walker Syndrome Patients: A Systematic Review of Case Reports.
J Child Neurol
. 2017 Sep;32(10):886–902.
7.
Barkovich AJ, Kjos BO, Norman D, Edwards MS. Revised classification of posterior fossa cysts and cystlike malformations based on the results of multiplanar MR imaging.
AJR Am J Roentgenol
. 1989 Dec;153(6):1289–300.
8.
Hirsch JF, Pierre-Kahn A, Renier D, Sainte-Rose C, Hoppe-Hirsch E. The Dandy-Walker malformation. A review of 40 cases.
J Neurosurg
. 1984 Sep;61(3):515–22.
9.
Long A, Moran P, Robson S. Outcome of fetal cerebral posterior fossa anomalies.
Prenat Diagn
. 2006 Aug;26(8):707–10.
10.
Ohaegbulam SC, Afifi H. Dandy-Walker syndrome: incidence in a defined population of Tabuk, Saudi Arabia.
Neuroepidemiology
. 2001 May;20(2):150–2.
11.
Orphanet 2018: Prevalence and incidence of rare diseases: Bibliographic data, 2018 [accessed Sep 25]. Available from: https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf.
12.
Ecker JL, Shipp TD, Bromley B, Benacerraf B. The sonographic diagnosis of Dandy-Walker and Dandy-Walker variant: associated findings and outcomes.
Prenat Diagn
. 2000 Apr;20(4):328–32.
13.
Has R, Ermiş H, Yüksel A, Ibrahimoğlu L, Yildirim A, Sezer HD, et al. Dandy-Walker malformation: a review of 78 cases diagnosed by prenatal sonography.
Fetal Diagn Ther
. 2004 Jul-Aug;19(4):342–7.
14.
Chapman T, Mahalingam S, Ishak GE, Nixon JN, Siebert J, Dighe MK. Diagnostic imaging of posterior fossa anomalies in the fetus and neonate: part 2, Posterior fossa disorders.
Clin Imaging
. 2015 Mar-Apr;39(2):167–75.
15.
D’Antonio F, Khalil A, Garel C, Pilu G, Rizzo G, Lerman-Sagie T, et al. Systematic review and meta-analysis of isolated posterior fossa malformations on prenatal ultrasound imaging (part 1): nomenclature, diagnostic accuracy and associated anomalies.
Ultrasound Obstet Gynecol
. 2016 Jun;47(6):690–7.
16.
Salihu HM, Kornosky JL, Druschel CM. Dandy-Walker syndrome, associated anomalies and survival through infancy: a population-based study.
Fetal Diagn Ther
. 2008;24(2):155–60.
17.
Klein O, Pierre-Kahn A, Boddaert N, Parisot D, Brunelle F. Dandy-Walker malformation: prenatal diagnosis and prognosis.
Childs Nerv Syst
. 2003 Aug;19(7-8):484–9.
18.
Boddaert N, Klein O, Ferguson N, Sonigo P, Parisot D, Hertz-Pannier L, et al. Intellectual prognosis of the Dandy-Walker malformation in children: the importance of vermian lobulation.
Neuroradiology
. 2003 May;45(5):320–4.
19.
Bolduc ME, Limperopoulos C. Neurodevelopmental outcomes in children with cerebellar malformations: a systematic review.
Dev Med Child Neurol
. 2009 Apr;51(4):256–67.
20.
Blank MC, Grinberg I, Aryee E, Laliberte C, Chizhikov VV, Henkelman RM, et al. Multiple developmental programs are altered by loss of Zic1 and Zic4 to cause Dandy-Walker malformation cerebellar pathogenesis.
Development
. 2011 Mar;138(6):1207–16.
21.
Dyment DA, Sawyer SL, Chardon JW, Boycott KM. Recent advances in the genetic etiology of brain malformations.
Curr Neurol Neurosci Rep
. 2013 Aug;13(8):364.
22.
Aruga J, Millen KJ. ZIC1 Function in Normal Cerebellar Development and Human Developmental Pathology.
Adv Exp Med Biol
. 2018;1046:249–68.
23.
Imataka G, Yamanouchi H, Arisaka O. Dandy-Walker syndrome and chromosomal abnormalities.
Congenit Anom (Kyoto)
. 2007 Dec;47(4):113–8.
24.
Lei T, Feng JL, Xie YJ, Xie HN, Zheng J, Lin MF. Chromosomal aneuploidies and copy number variations in posterior fossa abnormalities diagnosed by prenatal ultrasonography.
Prenat Diagn
. 2017 Nov;37(11):1160–8.
25.
Tucker FD, Morris JK, Neville A, Garne E, Kinsner-Ovaskainen A, Lanzoni M, et al.; JRC Management Committee. EUROCAT: an update on its functions and activities.
J Community Genet
. 2018 Oct;9(4):407–10.
26.
Kinsner-Ovaskainen A, Lanzoni M, Garne E, Loane M, Morris J, Neville A, et al. A sustainable solution for the activities of the European network for surveillance of congenital anomalies: EUROCAT as part of the EU Platform on Rare Diseases Registration.
Eur J Med Genet
. 2018 Sep;61(9):513–7.
27.
Boyd PA, Haeusler M, Barisic I, Loane M, Garne E, Dolk H. Paper 1: the EUROCAT network–organization and processes.
Birth Defects Res A Clin Mol Teratol
. 2011 Mar;91(Suppl 1):S2–15.
28.
Guide EU. 1.4: Instruction for the registration of congenital anomalies [accessed Oct 8, 2018]. Available from: http://www.eurocat-network.eu/content/Full%20Guide%201%204%20version%2003_OCT2018.pdf.
29.
Greenlees R, Neville A, Addor MC, Amar E, Arriola L, Bakker M, et al. Paper 6: EUROCAT member registries: organization and activities.
Birth Defects Res A Clin Mol Teratol
. 2011 Mar;91(Suppl 1):S51–100.
30.
Garne E, Dolk H, Loane M, Wellesley D, Barisic I, Calzolari E, et al.; EUROCAT Working Group. Paper 5: Surveillance of multiple congenital anomalies: implementation of a computer algorithm in European registers for classification of cases.
Birth Defects Res A Clin Mol Teratol
. 2011 Mar;91(Suppl 1):S44–50.
31.
Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe.
Adv Exp Med Biol
. 2010;686:349–64.
32.
Calzolari E, Pierini A, Astolfi G, Bianchi F, Neville AJ, Rivieri F. Associated anomalies in multi-malformed infants with cleft lip and palate: an epidemiologic study of nearly 6 million births in 23 EUROCAT registries.
Am J Med Genet A
. 2007 Mar;143A(6):528–37.
33.
Morton CC, Metcalfe A, Yusuf K, Sibbald B, Wilson RD. The Impact of Prenatal Diagnosis of Selected Central Nervous System Anomalies for Prenatal Counselling Based on Significant Pregnancy Morbidity and Neonatal Outcomes.
J Obstet Gynaecol Can
. 2019 Feb;41(2):166–73.e1.
34.
Griffiths PD, Brackley K, Bradburn M, Connolly DJA, Gawne-Cain ML, Kilby MD, et al. Anatomical subgroup analysis of the MERIDIAN cohort: posterior fossa abnormalities.
Ultrasound Obstet Gynecol
. 2017 Dec;50(6):745–52.
35.
EUROCAT prevalence table 2018 [accessed Oct 8, 2018]. Available from: http://www.eurocat-network.eu/accessprevalencedata/prevalencetables.
36.
Garne E, Loane M, Addor MC, Boyd PA, Barisic I, Dolk H. Congenital hydrocephalus–prevalence, prenatal diagnosis and outcome of pregnancy in four European regions.
Eur J Paediatr Neurol
. 2010 Mar;14(2):150–5.
37.
Shankar P, Zamora C, Castillo M. Congenital malformations of the brain and spine.
Handb Clin Neurol
. 2016;136:1121–37.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.